EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT

Abstract

There is an important unmet need for timely, noninvasive, low-burden diagnostic tools to aid in Alzheimer’s disease evaluation. The AAA-BBM2 (PrecivityAD2™) blood test combines plasma amyloid beta (AB)42/40 Ratio and phosphorylated-tau217/non-phosphorylated-tau217 Ratio (%p-tau217) into a clinically-validated algorithm.

The paper